NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that it has been named one of New Jersey’s 50 Fastest Growing Companies of 2013 by NJBIZ, the state’s premier business news publication.
“Being recognized as one of the 50 Fastest Growing Companies in New Jersey is a great honor and a testament to our remarkable growth,” said Francois Nader, M.D., president and chief executive officer of NPS Pharmaceuticals. “It’s an exciting time to be a part of the NPS team as we enter our next phase of growth to become a premier global orphan drug company and continue to work hard each day to bring innovative therapies to patients suffering from rare diseases around the world.”
The NJBIZ 50 Fastest Growing Companies awards program celebrates New Jersey's most dynamic companies who progressively contribute to the success of the state's economic growth and stability. To qualify, companies had to meet selection criteria that included a revenue size of at least $500,000 within the past two out of three years and growth in revenue over a three-year period, dating from fiscal year 2010 to 2012.
NJBIZ and the program sponsors honored this year’s 50 fastest growing companies and announced their ranking live during an awards dinner and ceremony on November 19 at the Palace at Somerset Park in Somerset, New Jersey. The honorees will also be highlighted in a special supplement to NJBIZ on November 25.About NPS Pharmaceuticals NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013.